A new drug treatment called EcP has been approved by the Food and Drug Administration (FDA) for the treatment of chronic pain.
The drug, which is also used in cancer treatments, has been on the market since January, but it was not until recently that a generic version of the drug was approved.
According to a statement from the FDA, the new drug, called EcPA, is the first to be approved for the use of a combination of medications, called a combination drug.
The drug can be used in combination with other treatments to improve quality of life, reduce pain and increase productivity.
The FDA also said the drug has been tested on rats, mice and dogs and that the results showed it has been well tolerated and effective.
The drug is being sold under the brand name EcPA and it is priced at $8.50 per tablet.
EcPA is manufactured by Gilead Sciences, which has been working to develop a new type of opioid that is more potent than morphine, as well as other opioids.
It is the company’s first product to use the synthetic opioid drug, known as naloxone, which was developed by Purdue Pharma.
The announcement of EcPA comes at a time when the opioid epidemic has taken hold in the U.S. and is having a dramatic impact on the lives of many people.
The Drug Enforcement Administration (DEA) announced last week that it would not renew its opioid prescription program after only 10 months, citing an increase in overdose deaths and the opioid crisis in the United States.